跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BY-101
首页
药物
BY-101
BY-101
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
PUTATIVE TUMOR SUPPRESSOR MICRORNA-101 MODULATES THE CANCER EPIGENOME BY REPRESSING THE POLYCOMB GROUP PROTEIN EZH2
申请人: UNIV SOUTHERN CALIFORNIA
优先权: 2009
US
Exosome miR-101-3p and miR-101-3p antagonist and application thereof
申请人: AFFILIATED TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE OF HUAZHONG UNIV SCI & TECH
优先权: 2024
CN
MIL-101 (Fe)-PA as well as preparation method and application thereof
申请人: UNIV GUANGDONG PHARM
优先权: 2023
CN
Heart-nourishing cream for treating coronary heart disease and preparation method thereof
申请人: LIXIN YUNJIE FAMILY FARM
优先权: 2018
CN
Application of microRNA-101 (micro-ribonucleic acid-101) inhibitor in preparing medicaments for preventing or treating osteoarthritis
申请人: UNIV PEKING 3RD HOSPITAL
优先权: 2014
CN
Novel bifidobacterium longum as well as microbial preparation, product and application thereof
申请人: SHENZHEN JUNCHANGYI BIOTECHNOLOGY CO LTD
优先权: 2024
CN
Novel NMOFs (PMIL-101(Fe)) drug carrier and preparation method thereof
申请人: UNIV TIANJIN POLYTECHNIC
优先权: 2015
CN
Application of small molecular non-coding RNA gene miR-101 in preparation of drugs for treating nasopharynx cancer
申请人: NANFANG HOSPITAL SOUTHERN MEDICAL UNIV
优先权: 2014
CN
药物
反馈